US20160340414A1 - Rsv-specific antibodies and functional parts thereof - Google Patents

Rsv-specific antibodies and functional parts thereof Download PDF

Info

Publication number: US20160340414A1
Authority: US; United States
Prior art keywords: seq; sequence; variable region; chain variable; antibody
Prior art date: 2014-01-15
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

US15/111,610

Other languages

English (en)

Inventor

Nancy Ulbrandt

Nicole Kallewaard-LeLay

Andy Q. Yuan

Bettina Richter

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

MedImmune Ltd

Original Assignee

MedImmune LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-01-15

Filing date

2015-01-14

Publication date

2016-11-24

2015-01-14 Application filed by MedImmune LLC filed Critical MedImmune LLC

2015-01-14 Priority to US15/111,610 priority Critical patent/US20160340414A1/en

2016-08-26 Assigned to MEDIMMUNE, LLC reassignment MEDIMMUNE, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KALLEWAARD-LELAY, Nicole, ULBRANDT, NANCY, YUAN, Andy Q., RICHTER, BETTINA

2016-11-24 Publication of US20160340414A1 publication Critical patent/US20160340414A1/en

2022-03-22 Assigned to MEDIMMUNE LIMITED reassignment MEDIMMUNE LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MEDIMMUNE, LLC

2023-04-17 Assigned to MEDIMMUNE LIMITED reassignment MEDIMMUNE LIMITED ASSIGNEE CHANGE OF ADDRESS Assignors: MEDIMMUNE LIMITED

Status Abandoned legal-status Critical Current

Images

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
- C07K16/11—
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Definitions

the antibody or functional part comprises a heavy chain sequence variable region comprising a sequence which is at least 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the framework (i.e., non CDR) sequence of SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, or SEQ ID NO: 21.
the framework i.e., non CDR sequence of SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, or SEQ ID NO: 21.
the antibody or functional part may comprise at least one of the alternative heavy chain CDRs from Table 14 and may have at least one other CDR modification.
the antibody or functional part may comprise a heavy chain CDR1 sequence comprising a sequence which differs by one amino acid from NYIIN (SEQ ID NO: 1)
a heavy chain CDR2 sequence comprises a sequence which differs by one or two amino acids from GIIPVLGTVHYAPKFQG (SEQ ID NO: 2)
a heavy chain CDR3 sequence comprises a sequence which differs by one or two amino acid from ETALVVSTTYLPHYFDN (SEQ ID NO: 3)
a light chain CDR1 sequence comprises a sequence which differs by one amino acid from QASQDIVNYLN (SEQ ID NO: 4)
a light chain CDR2 sequence comprises a sequence which differs by one amino acid from VASNLET (SEQ ID NO: 5)
a light chain CDR3 sequence comprises a sequence which differs by one amino acid from

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Virology (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Mycology (AREA)
Engineering & Computer Science (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pulmonology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

US15/111,610 2014-01-15 2015-01-14 Rsv-specific antibodies and functional parts thereof Abandoned US20160340414A1 (en)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
US15/111,610 US20160340414A1 (en)	2014-01-15	2015-01-14	Rsv-specific antibodies and functional parts thereof

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201461927819P	2014-01-15	2014-01-15
US15/111,610 US20160340414A1 (en)	2014-01-15	2015-01-14	Rsv-specific antibodies and functional parts thereof
PCT/US2015/011391 WO2015108967A2 (en)	2014-01-15	2015-01-14	Rsv-specific antibodies and functional parts thereof

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
PCT/US2015/011391 A-371-Of-International WO2015108967A2 (en)	2014-01-15	2015-01-14	Rsv-specific antibodies and functional parts thereof

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
US16/003,455 Continuation US10689437B2 (en)	2014-01-15	2018-06-08	RSV-specific antibodies and functional parts thereof

Publications (1)

Publication Number	Publication Date
US20160340414A1 true US20160340414A1 (en)	2016-11-24

Family

ID=53543612

Family Applications (6)

Application Number	Title	Priority Date	Filing Date
US15/111,610 Abandoned US20160340414A1 (en)	2014-01-15	2015-01-14	Rsv-specific antibodies and functional parts thereof
US16/003,455 Active US10689437B2 (en)	2014-01-15	2018-06-08	RSV-specific antibodies and functional parts thereof
US16/864,454 Active US11186628B2 (en)	2014-01-15	2020-05-01	RSV-specific antibodies and functional parts thereof
US17/451,955 Active US11661449B2 (en)	2014-01-15	2021-10-22	RSV-specific antibodies and functional parts thereof
US18/302,400 Active US12173050B2 (en)	2014-01-15	2023-04-18	RSV-specific antibodies and functional parts thereof
US18/943,007 Pending US20250179153A1 (en)	2014-01-15	2024-11-11	Rsv-specific antibodies and functional parts thereof

Family Applications After (5)

Application Number	Title	Priority Date	Filing Date
US16/003,455 Active US10689437B2 (en)	2014-01-15	2018-06-08	RSV-specific antibodies and functional parts thereof
US16/864,454 Active US11186628B2 (en)	2014-01-15	2020-05-01	RSV-specific antibodies and functional parts thereof
US17/451,955 Active US11661449B2 (en)	2014-01-15	2021-10-22	RSV-specific antibodies and functional parts thereof
US18/302,400 Active US12173050B2 (en)	2014-01-15	2023-04-18	RSV-specific antibodies and functional parts thereof
US18/943,007 Pending US20250179153A1 (en)	2014-01-15	2024-11-11	Rsv-specific antibodies and functional parts thereof

Country Status (26)

Country	Link
US (6)	US20160340414A1 (nl)
EP (3)	EP3094353B1 (nl)
JP (4)	JP6836398B2 (nl)
KR (1)	KR102188437B1 (nl)
CN (2)	CN116355080A (nl)
AU (4)	AU2015206570A1 (nl)
CA (1)	CA2933200C (nl)
CY (2)	CY1123425T1 (nl)
DK (1)	DK3094353T3 (nl)
ES (1)	ES2795727T3 (nl)
FI (1)	FIC20230016I1 (nl)
FR (1)	FR23C1016I1 (nl)
HR (1)	HRP20200607T1 (nl)
HU (2)	HUE048855T2 (nl)
LT (2)	LT3094353T (nl)
LU (1)	LUC00305I2 (nl)
MX (1)	MX374517B (nl)
NL (1)	NL301228I2 (nl)
NO (1)	NO2023016I1 (nl)
PL (1)	PL3094353T3 (nl)
PT (1)	PT3094353T (nl)
RS (1)	RS60387B1 (nl)
SI (1)	SI3094353T1 (nl)
SM (1)	SMT202000282T1 (nl)
TW (1)	TWI705974B (nl)
WO (1)	WO2015108967A2 (nl)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10059757B2 (en)	2007-06-01	2018-08-28	Medimmune Limited	RSV-specific binding molecules and means for producing them
WO2019152600A1 (en) *	2018-01-31	2019-08-08	The Wistar Institute Of Anatomy And Biology	Nucleic acid antibody constructs for use against respiratory syncytial virus
US10689437B2 (en)	2014-01-15	2020-06-23	Medimmune, Llc	RSV-specific antibodies and functional parts thereof
US10774133B2 (en)	2017-03-01	2020-09-15	Medimmune Limited	Anti-RSV monoclonal antibody formulation
US12024553B2 (en)	2019-04-30	2024-07-02	Medimmune Limited	Dosage regimens for and compositions including anti-RSV antibodies

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP7265984B2 (ja) *	2016-10-21	2023-04-27	アディマブ，エルエルシー	抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法
CN111606993B (zh) *	2019-02-26	2022-06-28	中国科学院上海生命科学研究院	抗呼吸道合胞病毒的全人广谱中和抗体4f1及其应用
CA3229901A1 (en)	2021-09-13	2023-03-16	Medimmune Limited	Prevention of respiratory syncytial virus lower respiratory tract infection with nirsevimab
CN116987183B (zh) *	2022-07-22	2024-10-15	北京智仁美博生物科技有限公司	抗呼吸道合胞病毒中和性抗体及其用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5807715A (en)	1984-08-27	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5892019A (en)	1987-07-15	1999-04-06	The United States Of America, As Represented By The Department Of Health And Human Services	Production of a single-gene-encoded immunoglobulin
US6309853B1 (en)	1994-08-17	2001-10-30	The Rockfeller University	Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
WO2006050166A2 (en) *	2004-10-29	2006-05-11	Medimmune, Inc.	Methods of preventing and treating rsv infections and related conditions
US7632497B2 (en) *	2004-11-10	2009-12-15	Macrogenics, Inc.	Engineering Fc Antibody regions to confer effector function
BRPI0718197A2 (pt) *	2006-10-02	2014-09-30	Medarex Inc	Anticorpo monoclonal isolado, ou uma porção de ligação ao antígeno do mesmo, composição, imunoconjugado, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, e, métodos para preparar um anticorpo anti-cxcr4, para modular a atividade do cxcr4 em uma célula, e para estimular a mobilização de células tronco cd34+ da medula óssea para o sangue periférico em um indivíduo.
BRPI0808673A2 (pt)	2007-03-06	2014-08-12	Symphogen A/S	Anticorpos recombinantes para tratamento de infecções com vírus sinciciais respiratórios.
EP1997830A1 (en)	2007-06-01	2008-12-03	AIMM Therapeutics B.V.	RSV specific binding molecules and means for producing them
JP2010531890A (ja) *	2007-06-26	2010-09-30	メディミューン，エルエルシー	Ｒｓｖ感染症及び関連する症状の治療方法
US8092804B2 (en) *	2007-12-21	2012-01-10	Medimmune Limited	Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
BRPI0906490A2 (pt)	2008-01-15	2015-07-14	Abbott Lab	Vetores de expressão de mamífero melhorados e uso dos mesmos
AU2010271583B2 (en) *	2009-07-15	2015-02-12	Kling Biotherapeutics B.V.	Means and methods for producing high affinity antibodies
NZ599148A (en) *	2009-10-06	2014-08-29	Medimmune Ltd	Rsv-specific binding molecule
US8568726B2 (en) *	2009-10-06	2013-10-29	Medimmune Limited	RSV specific binding molecule
WO2011056697A1 (en) *	2009-10-28	2011-05-12	Medimmune, Llc	Topical methods of treating rsv infections and related conditions
AU2013234046B2 (en) *	2012-03-16	2017-09-07	University Health Network	Methods and compositions for modulating Toso activity
IN2014DN09951A (nl) *	2012-05-22	2015-08-14	Shire Human Genetic Therapies
SI2950886T1 (sl)	2013-02-01	2020-06-30	Medimmune, Llc	Epitopi proteina F respiratornega sincicijskega virusa
AU2015206570A1 (en)	2014-01-15	2016-07-14	Medimmune, Llc	RSV-specific antibodies and functional parts thereof
TWI761453B (zh)	2017-03-01	2022-04-21	英商梅迪繆思有限公司	抗rsv單株抗體配製物
CN110366429B (zh)	2017-03-01	2024-10-11	免疫医疗有限公司	单克隆抗体的配制品

2015
- 2015-01-14 AU AU2015206570A patent/AU2015206570A1/en not_active Abandoned
- 2015-01-14 KR KR1020167020393A patent/KR102188437B1/ko active Active
- 2015-01-14 ES ES15737068T patent/ES2795727T3/es active Active
- 2015-01-14 DK DK15737068.5T patent/DK3094353T3/da active
- 2015-01-14 RS RS20200640A patent/RS60387B1/sr unknown
- 2015-01-14 CN CN202211184987.8A patent/CN116355080A/zh active Pending
- 2015-01-14 EP EP15737068.5A patent/EP3094353B1/en active Active
- 2015-01-14 WO PCT/US2015/011391 patent/WO2015108967A2/en not_active Ceased
- 2015-01-14 PT PT157370685T patent/PT3094353T/pt unknown
- 2015-01-14 CA CA2933200A patent/CA2933200C/en active Active
- 2015-01-14 HU HUE15737068A patent/HUE048855T2/hu unknown
- 2015-01-14 HR HRP20200607TT patent/HRP20200607T1/hr unknown
- 2015-01-14 MX MX2016008639A patent/MX374517B/es active IP Right Grant
- 2015-01-14 CN CN201580003410.4A patent/CN105916520A/zh active Pending
- 2015-01-14 US US15/111,610 patent/US20160340414A1/en not_active Abandoned
- 2015-01-14 SI SI201531183T patent/SI3094353T1/sl unknown
- 2015-01-14 LT LTEP15737068.5T patent/LT3094353T/lt unknown
- 2015-01-14 JP JP2016541720A patent/JP6836398B2/ja active Active
- 2015-01-14 EP EP23215838.6A patent/EP4353316A3/en active Pending
- 2015-01-14 SM SM20200282T patent/SMT202000282T1/it unknown
- 2015-01-14 PL PL15737068T patent/PL3094353T3/pl unknown
- 2015-01-14 EP EP20161884.0A patent/EP3741390A1/en not_active Withdrawn
- 2015-01-15 TW TW104101373A patent/TWI705974B/zh active
2018
- 2018-06-08 US US16/003,455 patent/US10689437B2/en active Active
2020
- 2020-02-10 JP JP2020020602A patent/JP2020103293A/ja active Pending
- 2020-05-01 US US16/864,454 patent/US11186628B2/en active Active
- 2020-06-05 CY CY20201100509T patent/CY1123425T1/el unknown
- 2020-06-10 AU AU2020203831A patent/AU2020203831A1/en not_active Abandoned
2021
- 2021-06-25 AU AU2021204339A patent/AU2021204339B2/en active Active
- 2021-10-22 US US17/451,955 patent/US11661449B2/en active Active
2023
- 2023-01-27 JP JP2023010903A patent/JP2023052693A/ja active Pending
- 2023-04-18 US US18/302,400 patent/US12173050B2/en active Active
- 2023-04-25 CY CY2023011C patent/CY2023011I1/el unknown
- 2023-04-25 FR FR23C1016C patent/FR23C1016I1/fr active Active
- 2023-04-25 NO NO2023016C patent/NO2023016I1/no unknown
- 2023-04-26 NL NL301228C patent/NL301228I2/nl unknown
- 2023-04-26 FI FIC20230016C patent/FIC20230016I1/fi unknown
- 2023-04-27 LU LU00305C patent/LUC00305I2/fr unknown
- 2023-04-28 LT LTPA2023514C patent/LTC3094353I2/lt unknown
- 2023-05-02 HU HUS2300019C patent/HUS2300019I1/hu unknown
2024
- 2024-11-11 US US18/943,007 patent/US20250179153A1/en active Pending
2025
- 2025-01-09 JP JP2025003702A patent/JP2025063143A/ja active Pending
- 2025-02-14 AU AU2025201056A patent/AU2025201056A1/en active Pending

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10730931B2 (en)	2007-06-01	2020-08-04	Medimmune Limited	RSV-specific binding molecules and means for producing them
US10059757B2 (en)	2007-06-01	2018-08-28	Medimmune Limited	RSV-specific binding molecules and means for producing them
US11661449B2 (en)	2014-01-15	2023-05-30	Medimmune Limited	RSV-specific antibodies and functional parts thereof
US10689437B2 (en)	2014-01-15	2020-06-23	Medimmune, Llc	RSV-specific antibodies and functional parts thereof
US11186628B2 (en)	2014-01-15	2021-11-30	Medimmune, Llc	RSV-specific antibodies and functional parts thereof
US12173050B2 (en)	2014-01-15	2024-12-24	Medimmune Limited	RSV-specific antibodies and functional parts thereof
US10774133B2 (en)	2017-03-01	2020-09-15	Medimmune Limited	Anti-RSV monoclonal antibody formulation
US11286294B2 (en)	2017-03-01	2022-03-29	Medimmune Limited	Anti-RSV monoclonal antibody formulation
US11667698B2 (en)	2017-03-01	2023-06-06	Medimmune Limited	Anti-RSV monoclonal antibody formulation
CN111936513A (zh) *	2018-01-31	2020-11-13	威斯塔解剖学和生物学研究所	用于抗呼吸道合胞病毒的核酸抗体构筑体
US20210047390A1 (en) *	2018-01-31	2021-02-18	The Wistar Institute Of Anatomy And Biology	Nucleic acid antibody constructs for use against respiratory syncytial virus
WO2019152600A1 (en) *	2018-01-31	2019-08-08	The Wistar Institute Of Anatomy And Biology	Nucleic acid antibody constructs for use against respiratory syncytial virus
US12024553B2 (en)	2019-04-30	2024-07-02	Medimmune Limited	Dosage regimens for and compositions including anti-RSV antibodies

Also Published As

Publication number	Publication date
NL301228I2 (nl)	2023-09-13
LTC3094353I2 (nl)	2025-07-10
US11186628B2 (en)	2021-11-30
US20190106482A1 (en)	2019-04-11
JP6836398B2 (ja)	2021-03-03
JP2023052693A (ja)	2023-04-11
KR102188437B1 (ko)	2020-12-08
JP2025063143A (ja)	2025-04-15
PT3094353T (pt)	2020-06-08
SMT202000282T1 (it)	2020-07-08
CN105916520A (zh)	2016-08-31
FIC20230016I1 (fi)	2023-04-26
CN116355080A (zh)	2023-06-30
TWI705974B (zh)	2020-10-01
US11661449B2 (en)	2023-05-30
BR112016015044A2 (pt)	2017-09-19
AU2025201056A1 (en)	2025-03-06
RU2016133247A3 (nl)	2019-01-16
TW201612191A (en)	2016-04-01
SI3094353T1 (sl)	2020-07-31
NO2023016I1 (no)	2023-04-25
HK1225992A1 (en)	2017-09-22
MX374517B (es)	2025-03-06
JP2017504321A (ja)	2017-02-09
ES2795727T3 (es)	2020-11-24
AU2020203831A1 (en)	2020-07-02
CA2933200A1 (en)	2015-07-23
US20220098285A1 (en)	2022-03-31
US20250179153A1 (en)	2025-06-05
BR112016015044A8 (pt)	2023-04-11
CY2023011I2 (el)	2023-11-15
WO2015108967A3 (en)	2015-09-03
AU2021204339A1 (en)	2021-07-22
EP4353316A2 (en)	2024-04-17
ES2795727T9 (en)	2026-01-21
NL301228I1 (nl)	2023-05-03
CY1123425T1 (el)	2021-12-31
JP2020103293A (ja)	2020-07-09
RU2016133247A (ru)	2018-02-20
PL3094353T3 (pl)	2020-09-07
EP3094353A4 (en)	2017-09-06
EP3094353B1 (en)	2020-04-01
HUE048855T2 (hu)	2020-08-28
WO2015108967A8 (en)	2015-10-01
US12173050B2 (en)	2024-12-24
LUC00305I2 (nl)	2025-09-22
US20230365660A1 (en)	2023-11-16
EP4353316A3 (en)	2024-08-21
CY2023011I1 (el)	2023-11-15
EP3741390A1 (en)	2020-11-25
HUS2300019I1 (hu)	2023-05-28
FR23C1016I1 (fr)	2023-06-23
US20200331989A1 (en)	2020-10-22
LT3094353T (lt)	2020-08-10
MX2016008639A (es)	2017-02-15
WO2015108967A2 (en)	2015-07-23
DK3094353T3 (da)	2020-06-02
LTPA2023514I1 (nl)	2023-05-25
HRP20200607T1 (hr)	2020-07-10
RS60387B1 (sr)	2020-07-31
AU2015206570A1 (en)	2016-07-14
US10689437B2 (en)	2020-06-23
CA2933200C (en)	2025-05-06
KR20160104018A (ko)	2016-09-02
AU2021204339B2 (en)	2024-11-14
EP3094353A2 (en)	2016-11-23

Publication	Publication Date	Title
US12173050B2 (en)	2024-12-24	RSV-specific antibodies and functional parts thereof
US8124092B2 (en)	2012-02-28	Antibodies against H5N1 strains of influenza A virus
WO2017092645A1 (zh)	2017-06-08	一种抗呼吸道合胞病毒的全人源抗体
JP2024522670A (ja)	2024-06-21	呼吸器合胞体ウイルスに対する抗体及びその使用
US20240409621A1 (en)	2024-12-12	Antibody for recognizing rsv pre-f protein and use thereof
JP6538151B2 (ja)	2019-07-03	抗ｃ型肝炎抗体及びその抗原結合断片
HK40109087A (en)	2024-11-29	Rsv-specific antibodies and functional parts thereof
HK40041855A (en)	2021-08-27	Rsv-specific antibodies and functional parts thereof
RU2785598C2 (ru)	2022-12-09	Rsv-специфичные антитела и их функциональные части
HK1225992B (en)	2020-12-04	Rsv-specific antibodies and functional parts thereof
BR112016015044B1 (pt)	2024-04-02	Anticorpos específicos para rsv e partes funcionais dos mesmos
US20250382354A1 (en)	2025-12-18	Cross-specific antibodies, uses and methods for discovery thereof

Legal Events

Date	Code	Title	Description
2016-08-26	AS	Assignment	Owner name: MEDIMMUNE, LLC, MARYLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ULBRANDT, NANCY;KALLEWAARD-LELAY, NICOLE;YUAN, ANDY Q.;AND OTHERS;SIGNING DATES FROM 20150603 TO 20150611;REEL/FRAME:039555/0631
2018-06-18	STCB	Information on status: application discontinuation	Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION
2022-03-22	AS	Assignment	Owner name: MEDIMMUNE LIMITED, GREAT BRITAIN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MEDIMMUNE, LLC;REEL/FRAME:059346/0018 Effective date: 20220216
2023-04-17	AS	Assignment	Owner name: MEDIMMUNE LIMITED, UNITED KINGDOM Free format text: ASSIGNEE CHANGE OF ADDRESS;ASSIGNOR:MEDIMMUNE LIMITED;REEL/FRAME:063350/0476 Effective date: 20230417